Literature DB >> 19071154

Sulforaphane protects against cytokine- and streptozotocin-induced beta-cell damage by suppressing the NF-kappaB pathway.

Mi-Young Song1, Eun-Kyung Kim, Woo-Sung Moon, Jin-Woo Park, Hyung-Jin Kim, Hong-Seob So, Raekil Park, Kang-Beom Kwon, Byung-Hyun Park.   

Abstract

Sulforaphane (SFN) is an indirect antioxidant that protects animal tissues from chemical or biological insults by stimulating the expression of several NF-E2-related factor-2 (Nrf2)-regulated phase 2 enzymes. Treatment of RINm5F insulinoma cells with SFN increases Nrf2 nuclear translocation and expression of phase 2 enzymes. In this study, we investigated whether the activation of Nrf2 by SFN treatment or ectopic overexpression of Nrf2 inhibited cytokine-induced beta-cell damage. Treatment of RIN cells with IL-1beta and IFN-gamma induced beta-cell damage through a NF-kappaB-dependent signaling pathway. Activation of Nrf2 by treatment with SFN and induction of Nrf2 overexpression by transfection with Nrf2 prevented cytokine toxicity. The mechanism by which Nrf2 activation inhibited NF-kappaB-dependent cell death signals appeared to involve the reduction of oxidative stress, as demonstrated by the inhibition of cytokine-induced H(2)O(2) production. The protective effect of SFN was further demonstrated by the restoration of normal insulin secreting responses to glucose in cytokine-treated rat pancreatic islets. Furthermore, pretreatment with SFN blocked the development of type 1 diabetes in streptozotocin-treated mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19071154     DOI: 10.1016/j.taap.2008.11.007

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  57 in total

Review 1.  Metabolic syndrome: pathophysiology, management, and modulation by natural compounds.

Authors:  Yogita Rochlani; Naga Venkata Pothineni; Swathi Kovelamudi; Jawahar L Mehta
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-06-22

2.  Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice.

Authors:  Yoko Yagishita; Akira Uruno; Dionysios V Chartoumpekis; Thomas W Kensler; Masayuki Yamamoto
Journal:  J Endocrinol       Date:  2019-01-01       Impact factor: 4.286

3.  Extracellular Matrix Remodeling and Modulation of Inflammation and Oxidative Stress by Sulforaphane in Experimental Diabetic Peripheral Neuropathy.

Authors:  Passant E Moustafa; Noha F Abdelkader; Sally A El Awdan; Osama A El-Shabrawy; Hala F Zaki
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

Review 4.  Nrf2-Keap1 signaling as a potential target for chemoprevention of inflammation-associated carcinogenesis.

Authors:  Joydeb Kumar Kundu; Young-Joon Surh
Journal:  Pharm Res       Date:  2010-03-31       Impact factor: 4.200

Review 5.  Sumoylation modulates oxidative stress relevant to the viability and functionality of pancreatic beta cells.

Authors:  Ping Yang; Shuang Hu; Fei Yang; Xiang-Qian Guan; Shi-Qiang Wang; Ping Zhu; Fei Xiong; Shu Zhang; Junfa Xu; Qi-Lin Yu; Cong-Yi Wang
Journal:  Am J Transl Res       Date:  2014-07-18       Impact factor: 4.060

6.  Targeting Nrf2 by dihydro-CDDO-trifluoroethyl amide enhances autophagic clearance and viability of β-cells in a setting of oxidative stress.

Authors:  Wenjuan Li; Weiwei Wu; Haibo Song; Fang Wang; Huanjie Li; Li Chen; Yimu Lai; Joseph S Janicki; Keith W Ward; Colin J Meyer; Xing Li Wang; Dongqi Tang; Taixing Cui
Journal:  FEBS Lett       Date:  2014-05-08       Impact factor: 4.124

Review 7.  Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much?

Authors:  Sih Min Tan; Judy B de Haan
Journal:  Redox Rep       Date:  2014-02-21       Impact factor: 4.412

8.  Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice.

Authors:  Lauren M Aleksunes; Scott A Reisman; Ronnie L Yeager; Michael J Goedken; Curtis D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

9.  Luteolin improves the impaired nerve functions in diabetic neuropathy: behavioral and biochemical evidences.

Authors:  Ming Li; Qiang Li; Qingsong Zhao; Jinchao Zhang; Jiang Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  The Keap1-Nrf2 system prevents onset of diabetes mellitus.

Authors:  Akira Uruno; Yuki Furusawa; Yoko Yagishita; Toshiaki Fukutomi; Hiroyuki Muramatsu; Takaaki Negishi; Akira Sugawara; Thomas W Kensler; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.